ICU Medical (Nasdaq: ICUI) is expected to report Q3 earnings on Oct. 15. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ICU Medical's revenues will expand 6.6% and EPS will expand 4.6%.

The average estimate for revenue is $81.5 million. On the bottom line, the average EPS estimate is $0.68.

Revenue details
 Last quarter, ICU Medical notched revenue of $77.3 million. GAAP reported sales were 0.7% lower than the prior-year quarter's $77.8 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, EPS came in at $0.63. GAAP EPS of $0.63 for Q2 were 6.0% lower than the prior-year quarter's $0.67 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 50.6%, 410 basis points better than the prior-year quarter. Operating margin was 17.5%, 50 basis points worse than the prior-year quarter. Net margin was 11.8%, 40 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $320.6 million. The average EPS estimate is $2.60.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 82 members out of 96 rating the stock outperform, and 14 members rating it underperform. Among 25 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 23 give ICU Medical a green thumbs-up, and two give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ICU Medical is outperform, with an average price target of $58.50.